TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26023213
Drug: 8‐week Internet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐week Internet‐based pain coping skills training (PCST) protocol in addition to a 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Study: 26023213
Drug: 24‐week standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Study: 17634479
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in EGFR low group (n = 113)
Study: 17634479
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in EGFR high group (n = 73)
Study: 8210253
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) administered by drip infusion for 2 hours (group A)
Study: 3513884
Drug: Imipramine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 250 mg for four weeks
Study: 25170796
Drug: Trospium 30
Normalized name: trospium 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium 30 mg/day + Solifenacin 10 mg/day
Study: 20196149
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) therapy
Study: 18554862
Drug: 17-beta-estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta-estradiol (2 mg/day)
Study: 18554862
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of soy isoflavones and 17-beta-estradiol
Study: 8244135
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg gliadin (group A)
Study: 8244135
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg gliadin (group B)
Study: 3513568
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (250 mg per day for 3 months)
Study: 31304600
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen (625 IU anti-D at 28 and 34 weeks)
Study: 9164228
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen
Study: 27651506
Drug: Crushed intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed intranasal ER morphine
Study: 29849845
Drug: Morphine ARER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine ARER
Study: 27776098
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal blockade with 10 mL of bupivacaine 0.25% with epinephrine 1:300,000
Study: 11167480
Drug: Intravenous Buscopan
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Buscopan 20 mg
Study: 9571344
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LIS) injected 20 min before the meal
Study: 9571344
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LIS) injected 15 min after the meal
Study: 9571344
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (REG) injected 40 min before the meal
Study: 9571344
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (REG) injected 20 min before the meal
Study: 9571344
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (REG) injected immediately before the meal
Study: 7831946
Drug: Rapid Infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Infusion system (Haemonetics Corp., Braintree, MA)
Study: 7831946
Drug: Conventional iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional iv volume administration (37 degrees C) using pressure infusion bags
Study: 26341720
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training in combination with nutrient supplementation (RTS)
Study: 16608953
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 20 ppm for 12 hours
Study: 25140772
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhaled nitric oxide)
Study: 7547087
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 120 mg with antacid (Maalox)
Study: 7547087
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 120 mg fasting
Study: 2179584
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered bacterial extract
Study: 23278131
Drug: Doxycycline monotherapy
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline monotherapy PO
Study: 21367495
Drug: Low glucose
Normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glucose intake (2.5 mg kg(‐1) min(‐1))
Study: 21367495
Drug: Standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose intake (5.0 mg kg(‐1) min(‐1))
Study: 21367495
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid intake (1.5 g kg(‐1) day(‐1))
Study: 21367495
Drug: High amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High amino acid intake (3.0 g kg(‐1) day(‐1))
Study: 21367495
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (80 mU m(‐2) min(‐1))
Study: 19722799
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + Xan‐CHX gel treatment
Study: 19722799
Drug: SRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP treatment
Study: 9280178
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil (average ALA intake: 5.9 g/d)
Study: 26003683
Drug: Conjugated Linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Linoleic Acid (CLA) 4 × 0.8 g day(‐1)
Study: 2859043
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg betaxolol
Study: 31262573
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of tramadol 1 mg/kg (group T)
Study: 9117452
Drug: Dextrin sulphate
Normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrin sulphate (D2S) gel
Study: 8174967
Drug: CCK‐33 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐33 (0.5 IDU.kg‐1.h‐1) during 15 mmol/l hyperglycaemia
Study: 8174967
Drug: CCK‐33 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐33 (1.0 IDU.kg‐1.h‐1) during 15 mmol/l hyperglycaemia
Study: 3956116
Drug: Gold therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold therapy (Auromyose) in the same dosage schedule as before the study
Study: 3956116
Drug: Placebo (gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gold in a suspension diluted 1/100)
Study: 29208618
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 mg two times per day)
Study: 17577462
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg/d
Study: 17577462
Drug: Delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 30 mg/d
Study: 17577462
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Manidipine and Delapril
Study: 2212409
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of aqueous beclomethasone diproprionate nasal spray
Study: 2212409
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required use of aqueous beclomethasone diproprionate nasal spray
Study: 27789268
Drug: 1-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day antibiotic regimen (group B)
Study: 25329681
Drug: Salmeterol/Fluticasone Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 µg once daily for 12 weeks
Study: 22092536
Drug: Paracetamol (APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (APAP 1 g) + Saline (placebo)
Study: 22092536
Drug: Paracetamol (APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (APAP 1 g) + Naloxone (Nal 8 mg)
Study: 22092536
Drug: Placebo (pl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (pl) + Naloxone (Nal 8 mg)
Study: 31744796
Drug: PBS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBS treatment
Study: 21854752
Drug: Clodronate (CLO)
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (CLO) treatment
Study: 19473513
Drug: PACAM nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACAM nutrition supplement
Study: 7539635
Drug: FK 506
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 506 (tacrolimus) at a starting dose of 0.15 mg/kg/day for 12 months
Study: 30654054
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet
Study: 7854920
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. acetazolamide
Study: 2671560
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months supervised daily RMP 600 mg, ETH 500 mg and DDS 100 mg or CLO 100 mg
Study: 23891363
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (FA) 45 mg + Rosuvastatin (R) 5 mg for 8 weeks, then 10 mg for 8 additional weeks
Study: 23891363
Drug: Rosuvastatin (R)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (R) 5 mg for 8 weeks, then 10 mg for 8 additional weeks
Study: 19484433
Drug: IDD Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDD Therapy (Intervertebral Differential Dynamics Therapy) with traction weight systematically increased until 50% of a person's body weight plus 4.45 kg (10 lb) was reached.
Study: 19484433
Drug: IDD Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDD Therapy and SHAM group (both groups received standard conservative therapeutic care and 20 sessions).
Study: 16624438
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity formula proposed by McAuley
Study: 12177686
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/day
Study: 14560062
Drug: Galantamine (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (continuous treatment)
Study: 2008110
Drug: Low-dose allopurinol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose allopurinol (total dose 1200 mg)
Study: 2008110
Drug: High-dose allopurinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose allopurinol (total dose 2400 mg)
Study: 18290855
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg
Study: 21991729
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg/kg bolus followed by 0.4 microg/kg/hr infusion)
Study: 11641075
Drug: Intrarectal quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal quinine (QIR) 20 mg/kg in solution with 2 ml of water, followed by 15 mg/kg/8 h for cerebral malaria; 30 mg/kg followed by 20 mg/kg/12 h for severe malaria.
Study: 7906384
Drug: Didanosine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (500 mg per day)
Study: 7906384
Drug: Zalcitabine (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalcitabine (2.25 mg per day)
Study: 1982648
Drug: Potenlini treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potenlini treatment (daily intravenous drip of 60‐100 ml for 3 days)
Study: 1982648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other measures of treatment same as therapeutic group)
Study: 9385238
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment
Study: 19846008
Drug: Low-tidal-volume subgroup
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-tidal-volume subgroup (V(T)e ≤6 ml/kg)
Study: 11686231
Drug: Acid-suppressant treatment
Normalized name: undecylenic acid Topical Solution [Hongo Killer Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-suppressant treatment alone (lansoprazole)
Study: 9231834
Drug: Lisinopril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10, 20, or 40 mg)
Study: 8136647
Drug: Mixt. 716
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixt. 716 treatment group
Study: 3524840
Drug: Etretinate therapy
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate therapy (4 months)
Study: 3524840
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after etretinate therapy)
Study: 29504793
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral treatment (ICBT) with systematic exposure
Study: 22052452
Drug: ronacaleret 100
Normalized name: Ronacaleret
DrugBank: Ronacaleret (DB05255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ronacaleret 100 mg once daily
Study: 22052452
Drug: teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide 20 µg subcutaneously once daily
Study: 22052452
Drug: alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 70 mg once weekly
Study: 27660922
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (twice a day for 5 days)
Study: 27059671
Drug: HydE (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: HydE (9 g daily for 6 months)
Study: 24311763
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily for 3 months followed by 200 mg daily for 21 months
Study: 22912452
Drug: Nicarbazin (NCZ)
Normalized name: Nicarbazin
DrugBank: Nicarbazin (DB11434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicarbazin (NCZ) at 125 mg/kg
Study: 15823830
Drug: Relcovaptan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relcovaptan (400 mg)
Study: 9578817
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment (RAI) with a median dose of 555 MBq
Study: 16397182
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment
Study: 2518859
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine nightly
Study: 23850859
Drug: Service brokerage
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Service brokerage intervention (personalised booklet and weekly telephone contact for 4 weeks post-release)
Study: 19365397
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin (study group)
Study: 18091183
Drug: Ahmed glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed glaucoma implant with mitomycin C (AGI+MMC)
Study: 8044941
Drug: ranolazine 120
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranolazine 120 mg tid
Study: 8044941
Drug: ranolazine 30
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranolazine 30 mg tid
Study: 8044941
Drug: ranolazine 60
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranolazine 60 mg tid
Study: 3378659
Drug: Netilmicin administered
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin administered intravenously or intramuscularly every 12 h at a dosage of 2.0-4.4 mg/kg (mean 3.5 mg/kg) for 5-15 days (mean 11 days)
Study: 3378659
Drug: Netilmicin administered
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin administered intravenously or intramuscularly
Study: 3378659
Drug: Netilmicin therapy
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin therapy
Study: 28377394
Drug: Zolpidem tartrate
Normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem tartrate (ZT) tablet plus SZRD granule placebo
Study: 22867037
Drug: High-dose alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcohol (0.8 g/kg)
Study: 12618532
Drug: Interferon‐α-2b (INF‐α)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐α-2b (INF‐α) and ribavirin therapy
Study: 3805473
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment
Study: 10375932
Drug: LLETZ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLETZ treatment
Study: 1997835
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus fluorouracil (combined therapy)
Study: 16128369
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg) added to ACE inhibitor therapy
Study: 16128369
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ACE inhibitors only)
Study: 10325520
Drug: placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (1 tablet/day)
Study: 10325520
Drug: finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: finasteride (5 mg/day)
Study: 31724147
Drug: Dysphagia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysphagia therapy (original treatment method)
Study: 26170625
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg twice a day)
Study: 21900636
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg orally every 12 hours
Study: 8549581
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (C, 0.4 g.kg‐1 body mass)
Study: 8549581
Drug: Placebo (P,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P, sodium chloride 0.045 g.kg‐1 body mass)
Study: 11725826
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 0.6 g, three times daily, for 12 weeks
Study: 25926408
Drug: Fine+LBG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine+LBG treatment (smaller, 0.4-μm mean droplet size with LBG)
Study: 25926408
Drug: Coarse treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse treatment (larger, 6-μm mean droplet size)
Study: 24282895
Drug: Information leaflet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information leaflet on antibiotics with delayed prescription
Study: 17356139
Drug: Topical fibrin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fibrin spray
Study: 9819070
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (50-200 mg/d)
Study: 661730
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg benzbromarone (Normurat)
Study: 7175716
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g probenecid
Study: 19701833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levothyroxine and liothyronine for at least 4 months
Study: 8067759
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice a day)
Study: 15239254
Drug: Pravastatin (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40-80 mg)
Study: 15239254
Drug: Gemcitabine (80-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (80-90 mg/m2 over 24 hours weekly in cycles of 4 weeks)
Study: 12362007
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention program including physical therapy
Study: 8020902
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg/day for 10 days, first intravenously then orally) plus intravenous bolus of amoxicillin plus clavulanic acid (1 g) before each endoscopy
Study: 8020902
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy only in cases of established or suspected infection